The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lumify Ophthalmic Solution, 0.025%, of Bausch & Lomb Inc.
Brimonidine Tartrate Ophthalmic Solution, 0.025% is indicated for the relief of redness of the eye. According to IQVIA data, the product recorded US sales of approximately $39 million for the twelve months ended September 2025.
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.
The company reported a 27.7% increase in consolidated net profit to Rs 261.48 crore on a 22.5% rise in net sales to Rs 1,695.36 crore in Q3 FY26 as compared with Q3 FY25.
The counter slipped 3.26% to Rs 1,736.60 on the BSE.